Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

Silvia Scalzo, Antonio Gengaro, Giovanni Boccoli, Rosalba Masciulli, Gianfranco Giannella, G. Salvo, Paolo Marolla, P. Carlini, Giorgio Massimini, E. E. Holdener, Ugo Testa, Federico Calabresi, Cesare Peschle

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Four patients out of twenty with renal cancer and melanoma undergoing cancer immunotherapy with interleukin 2 (IL-2) and interferon alpha-2 (IFN-α2) had laboratory evidence of hypothyroidism starting at cycle three to six, with a decline in serum thyroxine below normal and, in three cases, a rise in serum thyrotropin and thyroglobulin. One hypothyroid patient had elevated serum antimicrosomal antibody titres before the start of treatment and two others responded similarly during therapy. Three of the sixteen euthyroid patients also developed elevated titres of this antibody. Partial or complete remission was observed in seven of the patient-three of the four with hypothyroidism showed tumour regression. Thus IL-2 and IFN-α2 can cause hypothyroidism, presumably via induction or exacerbation of autoimmune thyroid reactions. The occurrence of hypothyroidism may be mediated by high-dose IL-2 (rather than by LAK cell therapy as previously suggested) and potentiated by IFN-α2.

Original languageEnglish
Pages (from-to)1152-1156
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume26
Issue number11-12
DOIs
Publication statusPublished - 1990

Fingerprint

Hypothyroidism
Interferon-alpha
Interleukin-2
Melanoma
Carcinoma
Kidney
Serum
Lymphokine-Activated Killer Cells
Antibodies
Thyroglobulin
Kidney Neoplasms
Thyrotropin
Therapeutics
Cell- and Tissue-Based Therapy
Thyroxine
Immunotherapy
Neoplasms
Thyroid Gland

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. / Scalzo, Silvia; Gengaro, Antonio; Boccoli, Giovanni; Masciulli, Rosalba; Giannella, Gianfranco; Salvo, G.; Marolla, Paolo; Carlini, P.; Massimini, Giorgio; Holdener, E. E.; Testa, Ugo; Calabresi, Federico; Peschle, Cesare.

In: European Journal of Cancer and Clinical Oncology, Vol. 26, No. 11-12, 1990, p. 1152-1156.

Research output: Contribution to journalArticle

Scalzo, S, Gengaro, A, Boccoli, G, Masciulli, R, Giannella, G, Salvo, G, Marolla, P, Carlini, P, Massimini, G, Holdener, EE, Testa, U, Calabresi, F & Peschle, C 1990, 'Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma', European Journal of Cancer and Clinical Oncology, vol. 26, no. 11-12, pp. 1152-1156. https://doi.org/10.1016/0277-5379(90)90275-X
Scalzo, Silvia ; Gengaro, Antonio ; Boccoli, Giovanni ; Masciulli, Rosalba ; Giannella, Gianfranco ; Salvo, G. ; Marolla, Paolo ; Carlini, P. ; Massimini, Giorgio ; Holdener, E. E. ; Testa, Ugo ; Calabresi, Federico ; Peschle, Cesare. / Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. In: European Journal of Cancer and Clinical Oncology. 1990 ; Vol. 26, No. 11-12. pp. 1152-1156.
@article{49cffd75594c43f9a56aac470d28de21,
title = "Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma",
abstract = "Four patients out of twenty with renal cancer and melanoma undergoing cancer immunotherapy with interleukin 2 (IL-2) and interferon alpha-2 (IFN-α2) had laboratory evidence of hypothyroidism starting at cycle three to six, with a decline in serum thyroxine below normal and, in three cases, a rise in serum thyrotropin and thyroglobulin. One hypothyroid patient had elevated serum antimicrosomal antibody titres before the start of treatment and two others responded similarly during therapy. Three of the sixteen euthyroid patients also developed elevated titres of this antibody. Partial or complete remission was observed in seven of the patient-three of the four with hypothyroidism showed tumour regression. Thus IL-2 and IFN-α2 can cause hypothyroidism, presumably via induction or exacerbation of autoimmune thyroid reactions. The occurrence of hypothyroidism may be mediated by high-dose IL-2 (rather than by LAK cell therapy as previously suggested) and potentiated by IFN-α2.",
author = "Silvia Scalzo and Antonio Gengaro and Giovanni Boccoli and Rosalba Masciulli and Gianfranco Giannella and G. Salvo and Paolo Marolla and P. Carlini and Giorgio Massimini and Holdener, {E. E.} and Ugo Testa and Federico Calabresi and Cesare Peschle",
year = "1990",
doi = "10.1016/0277-5379(90)90275-X",
language = "English",
volume = "26",
pages = "1152--1156",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11-12",

}

TY - JOUR

T1 - Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

AU - Scalzo, Silvia

AU - Gengaro, Antonio

AU - Boccoli, Giovanni

AU - Masciulli, Rosalba

AU - Giannella, Gianfranco

AU - Salvo, G.

AU - Marolla, Paolo

AU - Carlini, P.

AU - Massimini, Giorgio

AU - Holdener, E. E.

AU - Testa, Ugo

AU - Calabresi, Federico

AU - Peschle, Cesare

PY - 1990

Y1 - 1990

N2 - Four patients out of twenty with renal cancer and melanoma undergoing cancer immunotherapy with interleukin 2 (IL-2) and interferon alpha-2 (IFN-α2) had laboratory evidence of hypothyroidism starting at cycle three to six, with a decline in serum thyroxine below normal and, in three cases, a rise in serum thyrotropin and thyroglobulin. One hypothyroid patient had elevated serum antimicrosomal antibody titres before the start of treatment and two others responded similarly during therapy. Three of the sixteen euthyroid patients also developed elevated titres of this antibody. Partial or complete remission was observed in seven of the patient-three of the four with hypothyroidism showed tumour regression. Thus IL-2 and IFN-α2 can cause hypothyroidism, presumably via induction or exacerbation of autoimmune thyroid reactions. The occurrence of hypothyroidism may be mediated by high-dose IL-2 (rather than by LAK cell therapy as previously suggested) and potentiated by IFN-α2.

AB - Four patients out of twenty with renal cancer and melanoma undergoing cancer immunotherapy with interleukin 2 (IL-2) and interferon alpha-2 (IFN-α2) had laboratory evidence of hypothyroidism starting at cycle three to six, with a decline in serum thyroxine below normal and, in three cases, a rise in serum thyrotropin and thyroglobulin. One hypothyroid patient had elevated serum antimicrosomal antibody titres before the start of treatment and two others responded similarly during therapy. Three of the sixteen euthyroid patients also developed elevated titres of this antibody. Partial or complete remission was observed in seven of the patient-three of the four with hypothyroidism showed tumour regression. Thus IL-2 and IFN-α2 can cause hypothyroidism, presumably via induction or exacerbation of autoimmune thyroid reactions. The occurrence of hypothyroidism may be mediated by high-dose IL-2 (rather than by LAK cell therapy as previously suggested) and potentiated by IFN-α2.

UR - http://www.scopus.com/inward/record.url?scp=0025641296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025641296&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(90)90275-X

DO - 10.1016/0277-5379(90)90275-X

M3 - Article

VL - 26

SP - 1152

EP - 1156

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11-12

ER -